Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal observed plasm...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji Eun, Yoon, Young‐Ran, Kim, Chang Ho, Lee, Jaehee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013650/
https://www.ncbi.nlm.nih.gov/pubmed/35191596
http://dx.doi.org/10.1111/1759-7714.14357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013650/
https://www.ncbi.nlm.nih.gov/pubmed/35191596
http://dx.doi.org/10.1111/1759-7714.14357

Ejemplares similares